SCHEMBL15701753

SCHEMBL15701753

CCOC(=O)c1cc(C(=O)O)ccc1-n1nc(C)c(Cl)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
PDE4B Q07343 2/20 0.47
PDE4D Q08499 2/20 0.43
LMNA P02545 2/20 0.42
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
OPRM1 P35372 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4C Q08493 1/20 0.41
KDM4E B2RXH2 2/20 0.40
NR3C1 P04150 1/20 0.40
MAPK1 P28482 1/20 0.39
TSHR P16473 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15701748 0.86 MAPT (0.47) POLBKMT2AMEN1PDE4BPDE4D
SCHEMBL15701757 0.86 TRPC1 (0.43) POLBKMT2AMEN1PDE4BPDE4D
SCHEMBL14061065 0.84 BCL2 (0.43) POLBKMT2AMEN1PDE4BPDE4D
SCHEMBL14061043 0.81 BCL2 (0.52)
SCHEMBL27920190 0.80 MEN1 (0.65) POLBKMT2AMEN1LMNAL3MBTL1
SCHEMBL27938684 0.79 POLB (0.63) POLBKMT2AMEN1LMNAL3MBTL1
SCHEMBL20502192 0.77 POLB (0.65) POLBKMT2AMEN1LMNAALDH1A1
SCHEMBL15701745 0.77 BCL2 (0.56)
SCHEMBL15701747 0.75 BCL2 (0.56) KMT2AMEN1ALDH1A1MAPK1TSHR
SCHEMBL15701746 0.74 BCL2 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 POLB 2219/4885KMT2A 2047/4885MEN1 4470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.